The estimated Net Worth of William Cavanagh is at least $320 Tysiąc dollars as of 22 October 2020. Mr. Cavanagh owns over 7,692 units of Perspective Therapeutics Inc stock worth over $10,634 and over the last 13 years he sold ISR stock worth over $0. In addition, he makes $309,706 as Chief Research and Development Officer at Perspective Therapeutics Inc.
Sign up
Mr. Cavanagh ISR stock SEC Form 4 insiders trading
William has made over 5 trades of the Perspective Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 7,692 units of ISR stock worth $4,000 on 22 October 2020.
The largest trade he's ever made was exercising 30,571 units of Perspective Therapeutics Inc stock on 27 May 2014 worth over $28,125. On average, William trades about 4,475 units every 146 days since 2011. As of 22 October 2020 he still owns at least 27,692 units of Perspective Therapeutics Inc stock.
You can see the complete history of Mr. Cavanagh stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Cavanagh biography
William Cavanagh III serves as Chief Research and Development Officer of the Company. He joined IsoRay Medical, Inc. in January 2010 and served as Vice President, Research and Development until March 3, 2016, other than serving as interim Chief Executive Officer for IsoRay from January 7, 2016 to February 14, 2016. He was appointed Chief Operating Officer of IsoRay effective March 3, 2016 and Chief Scientific Officer effective August 15, 2016. Immediately prior to joining IsoRay Medical, Mr. Cavanagh was engaged in the research and development of dendritic cell therapies for cancer and infectious diseases. He served as Chief Scientific Officer for Sangretech Biomedical, LLC for the six years prior to joining IsoRay Medical. At Sangretech, he oversaw the design and implementation of a novel cancer therapy. Mr. Cavanagh began his extensive career in cancer treatment technologies in the early 1990s, when he helped lead research and development of a therapy involving the insertion of radioactive sources directly into the prostate for the treatment of prostate cancer (prostate brachytherapy). He has designed several cancer treatment-related studies, is listed as an author on 34 peer-reviewed publications, and is the listed inventor on a U.S. patent application detailing a novel treatment for cancer. Mr. Cavanagh has also served as Director of the Haakon Ragde Foundation for Advanced Cancer Studies in Seattle, Washington, where he led the research foundation in the selection of viable research projects directed at treating advanced cancers. Mr. Cavanagh holds a B.S. in Biology from the University of Portland (Oregon) and attended two years of medical school before beginning his career in research management.
What is the salary of William Cavanagh?
As the Chief Research and Development Officer of Perspective Therapeutics Inc, the total compensation of William Cavanagh at Perspective Therapeutics Inc is $309,706. There are 3 executives at Perspective Therapeutics Inc getting paid more, with Lori Woods having the highest compensation of $416,524.
How old is William Cavanagh?
William Cavanagh is 54, he's been the Chief Research and Development Officer of Perspective Therapeutics Inc since 2019. There are 6 older and 9 younger executives at Perspective Therapeutics Inc. The oldest executive at Perspective Therapeutics Inc is Philip Vitale, 73, who is the Independent Director.
What's William Cavanagh's mailing address?
William's mailing address filed with the SEC is 350 HILLS STREET, SUITE 106, RICHLAND, WA, 99354.
Insiders trading at Perspective Therapeutics Inc
Over the last 18 years, insiders at Perspective Therapeutics Inc have traded over $0 worth of Perspective Therapeutics Inc stock and bought 1,651,741 units worth $855,397 . The most active insiders traders include Lori A Woods, Thomas C Lavoy oraz Dwight William Babcock. On average, Perspective Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $14,501. The most recent stock trade was executed by Lori A Woods on 13 April 2023, trading 187,500 units of ISR stock currently worth $114,375.
What does Perspective Therapeutics Inc do?
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.
What does Perspective Therapeutics Inc's logo look like?
Complete history of Mr. Cavanagh stock trades at Perspective Therapeutics Inc
Perspective Therapeutics Inc executives and stock owners
Perspective Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Lori Woods,
Chief Executive Officer, Director -
Lori A. Holmes-Woods,
CEO & Director -
Michael Krachon,
Executive Vice President of Sales and Marketing -
William Cavanagh,
Chief Research and Development Officer -
Michael L. Krachon,
Exec. VP of Sales & Marketing -
Jennifer Streeter,
COO & VP of HR -
William A. Cavanagh III,
Chief R&D Officer -
Krista Cline,
Senior Director of Operations, Corporate Secretary -
Philip Vitale,
Independent Director -
Alan Hoffmann,
Independent Director -
Jonathan Hunt,
Chief Financial Officer, Co-Principal Financial Officer -
Mark Austin,
Controller, Co-Principal Financial and Principal Accounting Officer -
Jennifer Streeter,
Chief Operating Officer, Vice President of Human Resources -
Michael McCormick,
Independent Chairman of the Board -
Krista Cline,
Sr. Director of Operations & Corp. Sec. -
Mark J. Austin CPA,
VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec. -
Jonathan R. Hunt,
CFO & Co-Principal Financial Officer -
Frank Morich,
Director -
Brien Ragle,
Controller -
Dwight William Babcock,
CEO -
Matthew Branson,
Principal Fin & Acct Officer -
Robert F Iii Williamson,
Director -
Thomas C Lavoy,
Director -
Albert Louis Smith,
Director -
Roger Girard,
CEO/President -
Robert R Kauffman,
Director -
Fredric Swindler,
Vice President -
David Swanberg,
EVP Operations & Secretary -
Stephen Boatwright,
Director